PA
PGNX

Profund Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Profund Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,321
Closed -$52K – 1259
2018
Q4 		$52K Sell
12,321
-2,772
-18% -$14.1K ﹤0.01% 1129
2018
Q3 		$95K Sell
15,093
-327
-2% -$2.51K ﹤0.01% 1517
2018
Q2 		$124K Buy
15,420
+1,775
+13% +$13.6K 0.01% 1456
2018
Q1 		$102K Buy
13,645
+2,001
+17% +$13.3K ﹤0.01% 1442
2017
Q4 		$69K Buy
+11,644
New +$70.7K ﹤0.01% 1442
2017
Q3 		– Sell
-14,223
Closed -$97K – 1481
2017
Q2 		$97K Buy
14,223
+688
+5% +$5.08K ﹤0.01% 1404
2017
Q1 		$128K Buy
+13,535
New +$135K 0.01% 1425

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Profund Advisors's PGNX Position: Q1 2019 in Review

Profund Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 12,321 shares — an estimated $52K sold.

Profund Advisors first reported a position in PGNX in Q1 2017 and held it in 7 quarters. The position peaked at $128K in Q1 2017. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • Profund Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Profund Advisors sold 12,321 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $52K.
  • Profund Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
  • Profund Advisors's Progenics Pharmaceuticals Inc position peaked at $128K in Q1 2017.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Profund Advisors's 13F filing for Q1 2019, filed 15 May 2019.